Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
237.48B
Market cap237.48B
Price-Earnings ratio
27.78
Price-Earnings ratio27.78
Dividend yield
2.22%
Dividend yield2.22%
Average volume
2.75M
Average volume2.75M
High today
$445.00
High today$445.00
Low today
$439.07
Low today$439.07
Open price
$444.72
Open price$444.72
Volume
1.70M
Volume1.70M
52 Week high
$450.98
52 Week high$450.98
52 Week low
$288.00
52 Week low$288.00

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $439.26. The company's market cap stands at 237.48B, with a P/E ratio of 27.78 and a dividend yield of 2.22%.

During the trading session on 2026-10-23, Amgen(AMGN) shares reached a daily high of $445.00 and a low of $439.07. At a current price of $439.26, the stock is +0.0% higher than the low and still -1.3% under the high.

Trading volume for Amgen(AMGN) stock has reached 1.7M, versus its average volume of 2.75M.

The stock's 52-week range extends from a low of $288.00 to a high of $450.98.

The stock's 52-week range extends from a low of $288.00 to a high of $450.98.

AMGN News

24/7 Wall St. 4h
AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?

Investing AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s? When a drugmaker's top product loses patent protection, the dividend usually...

AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?
TipRanks 7h
Amgen’s Bemarituzumab Trial Reaches Phase 3 Finish Line in Gastric Cancer

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Amgen’s latest update centers on a Phase 3 study called “Bemarituzumab or Placebo Plus Ch...

Investor's Business Daily 11h
At Amgen, Sustainability Is A Companywide Commitment - Investor's Business Daily

...

At Amgen, Sustainability Is A Companywide Commitment - Investor's Business Daily

Analyst ratings

51%

of 37 ratings
Buy
32.4%
Hold
51.4%
Sell
16.2%

More AMGN News

TipRanks 12h
Amgen price target raised to $480 from $450 at Oppenheimer

Oppenheimer analyst Jay Olson raised the firm’s price target on Amgen (AMGN) to $480 from $450 and keeps an Outperform rating on the shares ahead of quarterly r...

Simply Wall St 12h
Should Phase 3 Trial Win Require Action From Amgen Investors?

Amgen and AstraZeneca reported full Phase 3 CROSSING data showing Tezspire achieved statistically significant, clinically meaningful and sustained benefits in e...

The Motley Fool 1d
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?

Are you looking for a stable dividend payer or a high-growth medical innovator? Choosing between Amgen (AMGN +2.04%) and Eli Lilly & Co. (LLY +2.83%) depends on...

Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?
Simply Wall St 2d
Amgen Stock Looks Cheap Against Its Cash Flow Outlook

has ridden a powerful run in recent years, and with fresh drug data in the headlines, the real question for anyone looking at the stock is how well its current...

Amgen Stock Looks Cheap Against Its Cash Flow Outlook
TipRanks 3d
Amgen price target raised to $400 from $380 at Barclays

Barclays raised the firm’s price target on Amgen (AMGN) to $400 from $380 and keeps an Equal Weight rating on the shares as part of a Q3 earnings preview. The f...

24/7 Wall St. 3d
Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher

Investing Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher A European regulatory endorsement for an oral obesity pi...

Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher
Benzinga 3d
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study

AstraZeneca Plc (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) on Tuesday shared full results from the Phase 3 CROSSING trial of Tezspire (tezepelumab) in adolescents...

AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.